Enhancing immune cells to better fight tumors
Programming Metabolically Fit TILs for Immunotherapy
['FUNDING_OTHER'] · LIPO-IMMUNO TECH, LLC · NIH-10930154
This study is looking at ways to make your immune cells, called tumor-infiltrating lymphocytes, even better at finding and fighting cancer by teaching them to recognize more cancer markers, which could help improve treatment results for people with different types of cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LIPO-IMMUNO TECH, LLC (nih funded) |
| Locations | 1 site (MOUNT PLEASANT, UNITED STATES) |
| Trial ID | NIH-10930154 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the effectiveness of immune cells, specifically tumor-infiltrating lymphocytes (TILs), to target and destroy cancer cells. By genetically modifying these TILs to recognize multiple tumor antigens, the study aims to enhance their ability to control tumor growth when transferred back into patients. The approach involves using different growth factors to expand these modified TILs, potentially leading to better long-term outcomes for patients with various cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that have multiple antigenic targets and who are seeking advanced immunotherapy options.
Not a fit: Patients with tumors that do not express identifiable antigens or those who are not eligible for adoptive cell transfer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for cancer patients, improving their chances of recovery.
How similar studies have performed: Previous studies have shown promise in using modified TILs for cancer treatment, indicating that this approach has potential based on earlier successes.
Where this research is happening
MOUNT PLEASANT, UNITED STATES
- LIPO-IMMUNO TECH, LLC — MOUNT PLEASANT, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MEHROTRA, SHIKHAR — LIPO-IMMUNO TECH, LLC
- Study coordinator: MEHROTRA, SHIKHAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.